Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.

AIDS (London, England) - 12 Jun 2006

Cahn Pedro, Cassetti Isabel, Wood Robin, Phanuphak Praphan, Shiveley LeeAnn, Bethell Richard C, Sawyer James

Abstract excerpt

OBJECTIVE: Apricitabine (formerly AVX754 and SPD754) is a deoxycytidine analogue nucleoside reverse transcriptase inhibitor in clinical development for patients with HIV disease. This study evaluated the antiretroviral efficacy, tolerability and safety of apricitabine monotherapy, administered fo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Argentina
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Lymphocyte Count

Share to Reverse Transcriptase Inhibitors

Share to South Africa

Source

Identifiers

PMID: 16816554
DOI: 10.1097/01.aids.0000232233.41877.63

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16816554-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.PMID 16816554Read ↗

Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.Semantic proximity Read ↗

Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA PolymeraseSemantic proximity Read ↗

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.Semantic proximity Read ↗

Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.Semantic proximity Read ↗

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.Semantic proximity Read ↗

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.Semantic proximity Read ↗

Novel inhibitors of human immunodeficiency virus type 2 infectivitySemantic proximity Read ↗

Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.Semantic proximity Read ↗

Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.Semantic proximity Read ↗

Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.Semantic proximity Read ↗

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.Semantic proximity Read ↗

Short communication cellular pharmacology of 9-(beta-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.